Pharmafile Logo
Pharmafocus logo
Advanced Search

Astellas

Showing 13 posts of 103 posts found.

Astellas breaks ground on $95m antibody facility

January 20, 2011
Manufacturing and Production Agensys, Astellas, antibodies, antibody

Astellas has broken ground on a $95 million R&D and manufacturing facility in Santa Monica, USA, that will also serve …

News

Working Life: Astellas Pharma Europe’s chief operating officer

January 4, 2011
Business Services, Sales and Marketing Astellas, Ken Jones, Working Life, recruitment

Ken Jones tells Pharmafocus about how his field is changing, starting with how he found his way into his current …

News

Astellas signs stem cell partnership in liver disease

December 8, 2010
Research and Development Astellas, Cytori, Stem cells, liver disease, regenerative medicine

Astellas has teamed up with Cytori Therapeutics to develop a range of new stem cell treatments for liver disease and …

News
Nycomed COPD iPhone app

Digital Pharma: Pharma iPhone app update

October 15, 2010
Medical Communications Astellas, Boehringer, Digital Pharma blog, GlaxoSmithKline, Lundbeck, Menarini, Nycomed, Pfizer, Servier, Teva, app, iphone

The ranks of pharma iPhone apps are increasing all the time and recent months have seen new additions from Teva, …

News

Astellas taps into overactive bladder market with garden display

July 13, 2010
Medical Communications Astellas, Vesicare, disease awareness campaigns, overactive bladder

Astellas has launched a campaign to raise awareness of overactive bladder with the help of an award winning garden designer …

News

Astellas Pharma censured over advisory boards

July 9, 2010
Medical Communications, Sales and Marketing Astellas, Code of Practice, PMCPA

Astellas has been the subject of ‘naming and shaming’ advertisements in three medical journals after advisory board meetings it ran …

News
OSI Pharmaceuticals

Astellas set to acquire OSI Pharmaceuticals for $4bn

May 17, 2010
Research and Development, Sales and Marketing Astellas, M&A, MA, OSI

After four months and several failed bids Astellas Pharma has signed a definitive merger agreement with US biotech firm OSI …

News

Astellas eyes oncology growth

April 21, 2010
Research and Development, Sales and Marketing Astellas, Astellas Pharma Europe

Astellas Pharma Europe has set its sights on the oncology market, earmarking the therapy area as its latest “franchise focus” …

News
OSI Pharmaceuticals

OSI resists Astellas and invites other offers

March 16, 2010
Sales and Marketing Astellas, OSI, merger

A new takeover bid launched by Japanese pharma company Astellas for OSI Pharma has been rejected by the company’s board. …

News
OSI Pharmaceuticals

Astellas moves in on OSI Pharmaceuticals

March 2, 2010
Sales and Marketing Astellas, Astellas Pharma Europe, OSI

Astellas has launched a hostile takeover bid for OSI Pharmaceuticals, going directly to stockholders with a proposal that values the US …

News

Astellas signs European deal in pain management

June 23, 2009
Research and Development, Sales and Marketing Astellas

Astellas has struck a deal with Californian company NeurogesX to market in Europe a treatment for pain linked to peripheral …

News

CV Therapeutics rejects Astellas takeover bid

February 23, 2009
Sales and Marketing Astellas, CV Therapeutics

Biotech company CV Therapeutics has rejected a second take-over offer from Astellas, saying the Japanese group failed to recognise its …

News

Germany loses out in Astellas restructuring

August 2, 2007
Sales and Marketing Astellas, Germany

Astellas has announced streamlining and cutbacks to its operations across Europe, with operations in Germany losing staff in its saleforce …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025